Axio operates Forge and Lattice
Forge is Axio BioPharma's biologics development laboratory, and Lattice is software that connects data across companies. Lattice lets sponsors and manufacturing partners exchange approved records while each company keeps its data. Lab work showed how long teams spend reading records from different systems.
Teams reinterpret the same process records at each handoff
Biologics development generates valuable knowledge, but that knowledge breaks down as it moves across systems, teams, and organizations.
We started Axio with a practical conviction: AI would only matter in this space if it was grounded in real execution.
Forge gave us a direct view into:
- Fragmented process context
- Repeated manual interpretation
- Slow transfer of knowledge across stages, teams, and partners
It also made the opportunity clear:
a better system could emerge from the workflows themselves.
Field names from other systems did not match
Forge is our foundation. A lab where real work, real data, and real constraints shaped our perspective.
That experience led to a broader conclusion:
Process knowledge does not scale with the science. It fragments as work moves across systems and organizations.
That is what gave birth to Lattice.
Lattice is our response, a system that helps process understanding move more effectively across sites, partners, and programs.
Forge is the origin.
Lattice takes that work further.
Our approach
-
Start with real workflows
We build from how teams actually operate, not how systems are ideally designed.
-
Let execution inform the system
Our perspective comes from doing the work, not observing it.
-
Design for cross-organization reality
Biologics development spans sites and partners. The system has to reflect that.
Executive Team
Led by industry veterans with experience across biologics, commercialization, bioinformatics, and AI.
-
Justin Byers
Founder, CEO
Biopharma PD and commercial leader focused on building biomanufacturing services from the ground up.
-
Brian Staats
Co-founder, CTO
Technology leader specializing in bioinformatics with 20+ years in modeling, data science, and engineering.
Advisory Team
These advisors have worked in biologics development, manufacturing operations and commercialization.
-
Graham Brearley, PhD
Advisor
A BioPharma expert with 30+ years of experience in biologics development, operations leadership, and business growth through acquisitions, divestitures, and due diligence.
-
Greg Bleck, PhD
Advisor
Former VP of R&D at Catalent, co-founded Gala Design; developed technologies used in 20+ approved biopharmaceuticals, contributed to 175+ clinical trial molecules, and holds 20+ patents.
-
Patrick Haffey
Advisor
Life sciences executive with 20 years of experience building, qualifying, and commercializing new biopharma manufacturing businesses in the US and abroad.